Home

Garry E Menzel

CIK 1556064 · President and CEO · last filed 2026-06-29

Garry E Menzel is a President and CEO who has filed 36 SEC Form 4 insider transactions across 6 companies since 2012. The most recent filing, for BDTX, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$145.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $108.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$108.3K

Companies

6

Total Filings

36

Lifetime Open-Market Net

-$145.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BDTX Director 51,825 $2.09 $108.3K $0 8 2026-06-29
STOK Director — $32.96 — $0 6 2025-06-04
Adaptimmune Therapeutics PLC (ADAP) Delisted Director 275,703 $0.06 $16.0K -$43.4K 5 2024-07-01
TCR2 THERAPEUTICS INC. (TCRR) Delisted President and CEO 0 $1.48 $0 -$101.9K 15 2023-06-01
DVA Senior Vice President, Finance — $178.34 — $0 1 2013-09-11
Regulus Therapeutics Inc. (RGLS) Delisted COO & Executive VP, Finance — $8.16 — $0 1 2012-12-13

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-29 BDTX Grant (A) — $0 EDGAR
2025-06-12 BDTX Grant (A) — $0 EDGAR
2025-06-04 STOK Grant (A) — $0 EDGAR
2024-07-01 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2024-06-07 STOK Grant (A) — $0 EDGAR
2024-06-06 BDTX Grant (A) — $0 EDGAR
2023-07-10 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −47,702 -$43.4K EDGAR
2023-07-05 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2023-07-03 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2023-06-15 STOK Grant (A) — $0 EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.